Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crinecerfont in pediatric classic congenital adrenal hyperplasia
2023-509170-33-00Phase 3Authorised
- Sponsor
- Neurocrine Biosciences
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in 21-hydroxylase deficiency (21-OHD) comparing Crinecerfont with Placebo (2 arms). Primary endpoint: Change from baseline in serum androstenedione at Week 4. Planned start Nov 2021; status: authorised.
02
Drugs
crinecerfont
03
Conditions
21-hydroxylase deficiency (21-OHD)
Beyond the preview
Go deeper on 2023-509170-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509170-33-00.